GlassScriptPhysician profile
Talat M Nawas
NPI 1316976228
$666.89
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $158 · 2021: $19.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $114.80 | 2019-2021 | |
| Mylan Specialty L.P. | $101.96 | 2019-2020 | |
| Pfizer INC. | $71.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $59.64 | 2019-2020 | |
| Allergan, INC. | $56.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $53.21 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.07 | 2019 | |
| Biomerieux INC | $35.95 | 2019 | |
| Vifor Pharma, INC. | $33.66 | 2019-2020 | |
| Medtronic Vascular, INC. | $33.07 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $25.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $19.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.86 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talat Nawas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.